Point-counterpoint: the importance of "open access" to psychotropics for our patients.
The opposing arguments regarding so-called "open access" to psychotropic medicines for all physicians are outlined, with references. The reader is left to draw conclusions from the discussion or to utilize the points in presentations to politicians, the media, pharmacy and therapeutics committees, state Medicaid agencies, etc.
Schmetzer
Alan D
AD
Department of Psychiatry, Indiana University School of Medicine, 1111 W 10th St, Indianapolis, IN 26202-4800, USA. aschmetz@iupui.edu
Wernert
John J
JJ
D011307:Drug Prescriptions / Q000191:economics; D006297:Health Services Accessibility; D006801:Humans; D008484:Medicaid / Q000191:economics; D001523:Mental Disorders / Q000188:drug therapy*; D008605:Mental Health Services / Q000191:economics*; D011570:Psychiatry / Q000191:economics*; D011619:Psychotropic Drugs / Q000600:supply & distribution / Q000627:therapeutic use*; D014481:United States
D011619:Psychotropic Drugs